SLU-PP-332

FDA APPROVAL PENDING

Longevity

SLU-PP-332

Metabolic

Amino acid sequence

44

Amino acids

290.32da

Molecular weight

Peptide

Type

Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.

Top researched benefits

Overview of SLU-PP-332

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.

Metabolic Health

  • 12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.
  • Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.
  • Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.
  • Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.

Exercise Performance

  • 70% increase in running time and 45% increase in running distance in preclinical models.
  • Increased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.

Cardiovascular

  • Improved ejection fraction in heart failure models with reduced cardiac fibrosis.

Antiaging

  • First compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.

Kidney Protection

  • Reversed age-related albuminuria increase and prevented podocyte loss in elderly mice.

Storage

2-8°C refrigerated for research use

Frequency

Research only - not approved for human use

Typical Dose

NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP)

Cycle Duration

No human protocols established

Chemical Makeup

Key benefits

Exercise mimetic effects without physical activity

12% weight loss in 28 days

70% increased endurance

25% enhanced fatty acid oxidation

Improved insulin sensitivity

Reduced hepatic steatosis

Cardiac protection

Reversal of age-related mitochondrial dysfunction

Community interest

This peptide is still gaining traction in the community.

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

This overview is informational and based on aggregated descriptions from studies and user reports.

Was it helpful?Yes

SLU-PP-332 Molecular Information

View the scientifc details of SLU-PP-332.

44

Amino Acids

SLU-PP-332

Glu

Glu

Position 1

His

His

Position 2

Tyr

Tyr

Position 3

Asp

Asp

Position 4

Arg

Arg

Position 5

Pyl

Pyl

Position 6

?

?

Position 7

Tyr

Tyr

Position 8

Asn

Asn

Position 9

Asn

Asn

Position 10

Ala

Ala

Position 11

Pro

Pro

Position 12

His

His

Position 13

Thr

Thr

Position 14

His

His

Position 15

Ala

Ala

Position 16

Leu

Leu

Position 17

Glu

Glu

Position 18

Asn

Asn

Position 19

Tyr

Tyr

Position 20

Leu

Leu

Position 21

Met

Met

Position 22

Glu

Glu

Position 23

Thr

Thr

Position 24

His

His

Position 25

Tyr

Tyr

Position 26

Leu

Leu

Position 27

Glu

Glu

Position 28

Asn

Asn

Position 29

Glu

Glu

Position 30

Asx

Asx

Position 31

Glu

Glu

Position 32

Asn

Asn

Position 33

Glx

Glx

Position 34

Pyl

Pyl

Position 35

His

His

Position 36

Tyr

Tyr

Position 37

Asp

Asp

Position 38

Arg

Arg

Position 39

Ala

Ala

Position 40

Glx

Glx

Position 41

Ile

Ile

Position 42

Asp

Asp

Position 43

Glu

Glu

Position 44

Amino acid sequence
Glutamic acidPosition 1
HistidinePosition 2
TyrosinePosition 3
Aspartic acidPosition 4
ArgininePosition 5
PyrrolysinePosition 6
?Position 7
TyrosinePosition 8
AsparaginePosition 9
AsparaginePosition 10
AlaninePosition 11
ProlinePosition 12
HistidinePosition 13
ThreoninePosition 14
HistidinePosition 15
AlaninePosition 16
LeucinePosition 17
Glutamic acidPosition 18
AsparaginePosition 19
TyrosinePosition 20
LeucinePosition 21
MethioninePosition 22
Glutamic acidPosition 23
ThreoninePosition 24
HistidinePosition 25
TyrosinePosition 26
LeucinePosition 27
Glutamic acidPosition 28
AsparaginePosition 29
Glutamic acidPosition 30
Aspartic acid or AsparaginePosition 31
Glutamic acidPosition 32
AsparaginePosition 33
Glutamic acid or GlutaminePosition 34
PyrrolysinePosition 35
HistidinePosition 36
TyrosinePosition 37
Aspartic acidPosition 38
ArgininePosition 39
AlaninePosition 40
Glutamic acid or GlutaminePosition 41
IsoleucinePosition 42
Aspartic acidPosition 43
Glutamic acidPosition 44

Molecular Weight

290.32Da

Chain Length

44Amino Acids

Type

Peptide

SLU-PP-332 Protocols

Research compound - IP injection in animals only. No human administration protocols established.

GoalDosageFrequencyRoute
Standard Metabolic Protocol502 week rangeIntraperitoneal injection (IP)
Acute Exercise Enhancement501 week rangeIntraperitoneal injection (IP)
Extended Treatment504 week rangeIntraperitoneal injection (IP)

Reconstitution Instructions

Materials needed:

Bacteriostatic water (BAC) requiredSterile technique essential

Steps to reconstitute

  1. WARNING: Not tested in humans - research only
  2. Do NOT use outside approved research protocols
  3. Dosing cannot be extrapolated from animals to humans
  4. No human clinical trials initiated as of 2025
  5. Oral formulation in development
  6. Consult medical professionals before experimental use

SLU-PP-332 Cycle

The SLU-PP-332 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.

Taking breaks between cycles may help maintain effectiveness and support better overall results.

Week 0-0
Metabolic shift toward fat oxidation within 2 hours; gene expression changes at 3-6 hours; enhanced exercise performance 1 hour post-dose
Week 0-0
Increased resting energy expenditure measurable; enhanced fatty acid oxidation by 25%; improved grip strength by day 6
Week 2-4
Up to 12% weight loss by day 28; dramatic fat mass reduction; improved glucose tolerance; 45-70% endurance improvements; reduced hepatic steatosis
Week 6-8
Cardiac improvements (ejection fraction, reduced fibrosis); age-related kidney dysfunction reversal; mitochondrial architecture restoration
Week 0-0
Sustained anti-aging effects in aging studies; continued tissue mitochondrial improvement; duration after discontinuation unknown

Dosing tools

SLU-PP-332 Peptide Dosage Calculator

Calculate peptide doses with our visual syringe guide.

0.3mL / 30 units

5 units

0.050 mL

1 mL

2 mL

3 mL

5 mL

Custom

Conversion: 1,000 mcg = 1 mg

Injection Results

Based on your vial and dilution inputs.

Safe concentration range

SLU-PP-332

SINGLE COMPOUND

Volume per injection

0.05

mL

Concentration

10.00

mg/mL

Doses per vial

20

doses

Total injections per vial

20 injections

How it works

Based on a 10 mg SLU-PP-332 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.

Research Purposes Only

These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.

Reference Guide

Dosing Cycle

Peptide
SLU-PP-332
Dosing
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP)
Dosing Frequency
Research only - not approved for human use
Cycle Duration
No human protocols established
Storage
2-8°C refrigerated for research use

Note: Triple agonist; microdose for fewer side effects

Reconstitution Tips

  • Use bacteriostatic water (BAC)contains 0.9% benzyl alcohol for preservation
  • Inject water slowlyaim down the vial wall, not directly onto powder
  • Never shakegently swirl or roll the vial until dissolved
  • Store properlyrefrigerate at 2-8°C after reconstitution
  • Use within 28 daysmost reconstituted peptides remain stable for about 4 weeks
  • Keep sterilealways clean vial tops with alcohol before drawing

Peptide Interactions

Research suggestions of SLU-PP-332 interactions with other common peptides and substances.

Weight

5am

Longevity

5-Amino-1MQ

COMPATIBLE

Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.

COMPATIBLE

Weight

ipa

Growth

Ipamorelin

COMPATIBLE

May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.

COMPATIBLE

Longevity

nad

Metabolic

NAD+

SYNERGISTIC

Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.

SYNERGISTIC

Weight

sem

Metabolic

Semaglutide

MONITOR

Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.

MONITOR

Weight

tir

Metabolic

Tirzepatide

MONITOR

Different mechanisms affecting weight loss and metabolism - combination could have additive effects.

MONITOR

Side effects

Monitor: Be careful when combining SLU-PP-332 with Semaglutide, Tirzepatide.

Contraindications

NOT FOR HUMAN USE - no approved human dose

No human clinical trials conducted

Potential interaction with diabetes medications

Stop signs

Severe hypoglycemia (especially with diabetes medications)

Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)

Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)

Kidney problems (reduced urination, swelling, severe back pain)

Severe headaches or neurological symptoms

Allergic reactions (rash, hives, difficulty breathing, swelling)

Bad signs

Any product marketed for human consumption is illegalUnknown purity or contamination without lab testingLack of proper HPLC or mass spectrometry verificationProducts without 'Research Use Only' labeling
Was it helpful?Yes

Comments

0.0

0 reviews

5

4

3

2

1

No comments yet

Be the first to share your experience. Your review helps others make more informed decisions.

Frequently asked questions

What benefits can peptides offer in research?

Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.

What are some exciting applications of peptides in modern science?

Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.

How do peptides influence health and wellness?

Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.

Where can I find the latest studies on peptide applications?

Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.

Are there any guidelines for using peptides in research?

Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.

What is the difference between peptides and proteins?

Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.

How should peptides be stored?

Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.

Can peptides be taken orally?

Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.

SLU-PP-332Research References

SLU-PP-332 is an emerging compound

4Research references

SLU-PP-332

SLU-PP-332 is an emerging compound

A Synthetic ERR Agonist Alleviates Metabolic Syndrome

Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis.

2024

Synthetic ERRα/β/γ Agonist Induces Acute Aerobic Exercise Response

Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers.

2023

Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction in Aging Kidney

21-month-old mice, 8-week treatment: Reversed age-related kidney decline, reduced albuminuria, prevented podocyte loss, restored mitochondrial architecture.

2023

Cardiac Protective Effects of Pan-ERR Agonists

Heart failure models, 6-week treatment: Improved ejection fraction, ameliorated cardiac fibrosis, improved survival, enhanced mitochondrial ultrastructure.

2021